From the American Academy of Ophthalmology

This retrospective review assessed the effect of aflibercept 2.0 mg in wet AMD patients with persistent fluid on regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg. Subjects were 28 patients (28 eyes) who had an average of 20 regular ranibizumab/bevacizumab injections. At one month, 89 percent showed anatomic improvement and 18 percent were dry after a single aflibercept injection. Central subfoveal thickness improved from 295 to 272 microns (p<0.001) after one aflibercept injection, with gains maintained at six months. However, visual acuity did not improve. British Journal of Ophthalmology, August 2013